Akèy › Kansè poumon › Oklahoma
Etid klinik pou Kansè poumon nan Oklahoma
20 etid pou Kansè poumon ap chèche patisipan nan sit nan Oklahoma.
Vil nan Oklahoma
Tèks ofisyèl etid la (Anglè)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Cancer Centers of Southwest Oklahoma Research, Lawton
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
- ak 1 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT04267848The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- University of Oklahoma, Oklahoma City
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT04585750Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mercy Hospital Oklahoma City, Oklahoma City
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT05334069Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
- Mercy Hospital Oklahoma City, Oklahoma City
Ap rekriteFaz 3
Laj 70 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06096844Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
- Integris Cancer Institute of Oklahoma, Oklahoma City
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT04181060Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- University of Oklahoma Health Sciences Center, Oklahoma City
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06498635A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Hightower Clinical, LLC ( Site 0084), Oklahoma City
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06312137Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
- INTEGRIS Cancer Institute of Oklahoma, Oklahoma City
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06712316Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- University of Oklahoma, Oklahoma City
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06128551Identification and Validation of Blood-Based Biomarkers for Early Detection of Asymptomatic Lung Cancer in High-Risk Heavy Smokers
- Site 101, Oklahoma City
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 30 a 80 · Tout sèks · Mizajou Sep 11, 2026 · NCT06816121The Vanguard Study: Testing a New Way to Screen for Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
Ap rekriteVolontè an sante akeyi
Laj 45 a 75 · Tout sèks · Mizajou Sep 2, 2026 · NCT06995898Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
- University of Oklahoma Health Sciences Center, Oklahoma City
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT06500481Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT05624996Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
- Xencor Investigative Site, Oklahoma City
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 3, 2026 · NCT05433142A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
- Sarah Cannon Research Institute University of Oklahoma, Oklahoma City
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 15, 2026 · NCT05652686Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- Cancer Centers of Southwest Oklahoma Research, Lawton
- University of Oklahoma Health Sciences Center, Oklahoma City
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jun 3, 2026 · NCT05642572Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- Cancer Centers of Southwest Oklahoma Research, Lawton
- University of Oklahoma Health Sciences Center, Oklahoma City
Ap rekriteFaz 2
18 Minutes · Tout sèks · Mizajou May 5, 2026 · NCT06031688Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- Cancer Centers of Southwest Oklahoma Research, Lawton
- University of Oklahoma Health Sciences Center, Oklahoma City
- Integris Southwest Medical Center, Oklahoma City
- ak 1 plis
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou May 5, 2026 · NCT06616584SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Tulsa
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
- Hightower Clinical, Oklahoma City
Ap rekriteEtid obsèvasyon
Laj 50 ak plis · Tout sèks · Mizajou Aug 5, 2025 · NCT06122077Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.